Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OCS
STRONG SELLOculis Holding AG · Healthcare · Switzerland · $672M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Oculis Holding AG is a clinical-stage biopharmaceutical company dedicated to developing innovative topical treatments for serious ophthalmic diseases. The company's competitive edge lies in its proprietary OCS-01 drug candidate and advanced formulation technologies, aiming to deliver therapeutic benefits directly to the eye without the need for injections or implants.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 1.0M | 5.0M | — |
| EPS | -13.98 | -3.67 | -2.62 | -2.33 | — | -2.08 | -2.15 | -2.10 | — |
| Shares | 32.7M | 36.6M | 43.7M | 58.0M | +77.1% | 60.4M | — | — | — |
| Debt | 0.8M | 0.7M | 1.5M | 2.9M | 54.0% | 2.8M | — | — | — |
| Equity | -121.0M | 115.8M | 90.7M | 242.2M | 44.6% | — | — | — | — |
| Op CF | -31.0M | -68.0M | -60.4M | -81.9M | — | -77.4M | — | — | — |
| Inv CF | -4.4M | -65.4M | -19.9M | -75.3M | — | — | — | — | — |
| Fin CF | 2.1M | 160.1M | 66.7M | 230.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OCS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OCS | Oculis Holding AG(you) | $672M | 7 | STRONG SELL |
| ACIU | AC Immune SA | $299M | 10 | STRONG SELL |
| MLTX | MoonLake Immunotherapeutics | $1.6B | 18 | STRONG SELL |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 24 | SELL |
| 0QNA.L | Basilea Pharmaceutica AG | $733M | 49 | HOLD |
| PHVS | Pharvaris N.V. | $2.4B | 26 | SELL |
| MOLN.SW | Molecular Partners AG | $147M | 22 | SELL |
| CRSP | CRISPR Therapeutics AG | $4.6B | 14 | STRONG SELL |
| IDIA.SW | Idorsia Ltd | $2.2B | 33 | SELL |
| BANB.SW | Bachem Holding AG | $6.7B | 52 | HOLD |
Peer medians: ROE 12.1% · P/E 25.2x · Gross margin 55.8%